This review is a summary of the evidence for dolutegravir (Tivicay) plus lamivudine for the treatment of HIV infection in newly diagnosed and virologically suppressed patients. The fixeddose combination tablet of dolutegravir 50 mg/lamivudine 300 mg (Dovato) is approved in New Zealand for the treatment of HIV-1 infection in adults and adolescents who have no known or suspected resistance to either antiretroviral component.1 Please note that Dovato is not currently funded in New Zealand however the combination is available as separate tablets of dolutegravir and lamivudine. This review is sponsored by GlaxoSmithKline (NZ) Ltd.
Please login below to download this issue (PDF)